Novo Nordisk A/S announces that CVS Caremark, the country's largest Pharmacy Benefit Manager has decided that Wegovy injection 2.4 mg, the most widely prescribed and studied GLP-1 for weight loss, will soon be the preferred GLP-1 medicine on its largest commercial template formularies
- Wegovy will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager in the US, effective July 1, 2025.
- Novo Nordisk is focused on new ways to drive access and affordability for Wegovy, the most widely prescribed and studied GLP-1 for weight loss that is fully available nationwide.
CVS Health beats by $0.55, reports revs in-line; raises FY25 EPS above consensus
- Reports Q1 (Mar) earnings of $2.25 per share, excluding non-recurring items, $0.55 better than the FactSet Consensus of $1.70; revenues rose 7.0% year/year to $94.59 bln vs the $93.66 bln FactSet Consensus.
- Co issues upside guidance for FY25, sees EPS of $6.00-6.20, excluding non-recurring items, vs. $5.92 FactSet Consensus and prior guidance of $5.75-6.00.
- Raised cash flow from operations guidance to approximately $7.0 billion from approximately $6.5 billion
- CVS Health to exit the individual exchange business
